ArticleNPJ breast cancer2023

Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer.

Ziyan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.